Cleared Traditional

K930130 - RHEUMELISA II SCL-70 ANTIBODY TEST KIT

K930130 is an FDA 510(k) clearance for RHEUMELISA II SCL-70 ANTIBODY TEST KIT, manufactured by Biowhittaker Molecular Applications, Inc.. The device is a Class 2 Immunology device with product code LLL cleared through the Traditional 510(k) pathway after a 70-day FDA review.

K930130 · Biowhittaker Molecular Applications, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1993
Decision
70d
Days
Class 2
Risk

K930130 is an FDA 510(k) clearance for the RHEUMELISA II SCL-70 ANTIBODY TEST KIT. Classified as Extractable Antinuclear Antibody, Antigen And Control (product code LLL), Class II - Special Controls.

Submitted by Biowhittaker Molecular Applications, Inc. (Walkersville, US). The FDA issued a Cleared decision on March 23, 1993 after a review of 70 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Biowhittaker Molecular Applications, Inc. devices

FDA 510(k) Submission Details - K930130

510(k) Number K930130 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 12, 1993
Decision Date March 23, 1993
Days to Decision 70 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
35d faster than avg
Panel avg: 105d · This submission: 70d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LLL Device Classification - Class 2, Special Controls

Product Code LLL Extractable Antinuclear Antibody, Antigen And Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LLL Extractable Antinuclear Antibody, Antigen And Control

All 144
Devices cleared under the same product code (LLL) and FDA review panel - the closest regulatory comparables to K930130.
DIASTAT ANTI-CENTROMERE KIT
K932877 · Shield Diagnostics, Ltd. · Oct 1993
SYNELISA JO-1 ANTIBODIES
K930281 · Elias U.S.A., Inc. · Apr 1993
SYNELISA SCL-70 ANTIBODIES
K930417 · Elias U.S.A., Inc. · Apr 1993
QUANTA LITE(TM) JO-1 ELISA KIT
K926562 · Inova Diagnostics, Inc. · Mar 1993
EN TYPING CIE KIT FOR DIAGNOSTIC USE
K925118 · The Binding Site, Ltd. · Feb 1993
ENA SCREENING CIE KIT FOR DIAGNOSTIC USE
K924262 · The Binding Site, Ltd. · Dec 1992